Cwm LLC Purchases 1,762 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Cwm LLC lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 60.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,664 shares of the company’s stock after purchasing an additional 1,762 shares during the quarter. Cwm LLC’s holdings in Neurocrine Biosciences were worth $643,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. First Horizon Advisors Inc. increased its holdings in shares of Neurocrine Biosciences by 10.5% in the fourth quarter. First Horizon Advisors Inc. now owns 782 shares of the company’s stock worth $103,000 after purchasing an additional 74 shares during the period. Quadrant Capital Group LLC grew its position in Neurocrine Biosciences by 3.9% in the fourth quarter. Quadrant Capital Group LLC now owns 2,075 shares of the company’s stock worth $273,000 after acquiring an additional 78 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its position in Neurocrine Biosciences by 3.2% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,530 shares of the company’s stock worth $333,000 after acquiring an additional 78 shares in the last quarter. Sunbelt Securities Inc. grew its position in Neurocrine Biosciences by 34.3% in the third quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock worth $37,000 after acquiring an additional 83 shares in the last quarter. Finally, Balentine LLC grew its position in Neurocrine Biosciences by 4.0% in the fourth quarter. Balentine LLC now owns 2,316 shares of the company’s stock worth $305,000 after acquiring an additional 89 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Eric Benevich sold 19,818 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the completion of the transaction, the insider now owns 40,778 shares of the company’s stock, valued at $5,438,154.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Neurocrine Biosciences news, insider Eric Benevich sold 19,818 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the completion of the transaction, the insider now owns 40,778 shares of the company’s stock, valued at $5,438,154.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stephen A. Sherwin sold 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $133.46, for a total transaction of $5,338,400.00. Following the transaction, the director now directly owns 26,504 shares of the company’s stock, valued at approximately $3,537,223.84. The disclosure for this sale can be found here. Over the last quarter, insiders sold 88,697 shares of company stock valued at $11,975,615. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Price Performance

NBIX stock opened at $134.57 on Friday. Neurocrine Biosciences, Inc. has a 1 year low of $93.02 and a 1 year high of $148.37. The company has a market cap of $13.54 billion, a P/E ratio of 37.07 and a beta of 0.36. The firm has a 50-day moving average of $137.06 and a 200 day moving average of $135.05.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.62). Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The company had revenue of $515.30 million during the quarter, compared to the consensus estimate of $512.21 million. On average, equities research analysts expect that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on NBIX. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research report on Wednesday, May 1st. UBS Group upped their price target on shares of Neurocrine Biosciences from $174.00 to $193.00 and gave the company a “buy” rating in a research report on Tuesday, May 28th. Canaccord Genuity Group upped their price target on shares of Neurocrine Biosciences from $154.00 to $164.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. HC Wainwright upped their price target on shares of Neurocrine Biosciences from $150.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. Finally, StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday. Six equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $152.00.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.